A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Gemcitabine (Primary) ; Napabucasin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms CanStem111P
- Sponsors Boston Biomedical
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 03 Jun 2017 According to a Boston Biomedical media release, trial design presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting.
- 18 May 2017 According to a Boston Biomedical media release, data from this study will be presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting.